Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
NYU Langone Health, Perlmutter Cancer Center, New York University School of Medicine, New York, New York.
Clin Adv Hematol Oncol. 2020 Oct;18(10):647-655.
With the introduction of PARP inhibitors into frontline chemotherapy, with or without bevacizumab, the hope exists that more women may be spared a recurrence of their ovarian cancer. Whether or not this proves to be true, the fact remains that many or most women with ovarian cancer will experience a recurrence requiring the use of additional active chemotherapy and targeted options. This manuscript summarizes the known data to date regarding the use of PARP inhibitors in the recurrent setting.
随着 PARP 抑制剂被引入一线化疗（联合或不联合贝伐珠单抗），更多的女性有望避免卵巢癌复发。无论这是否被证明是真的，事实上，许多或大多数患有卵巢癌的女性将经历复发，需要使用额外的有效化疗和靶向治疗。本文总结了迄今为止关于 PARP 抑制剂在复发性疾病中的应用的已知数据。
